MedTrace Logo

Dry Blood Spot Screening Test for Biliary Atresia（DBS-SCReBA）

NCT03898765 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2019-04-02

No results posted yet for this study

Summary

Our study aims to develop a screening test for biliary atresia (BA) using dry blood spot to improve patient survival by early diagnosis. Newborn screening dry blood spot will be examined for the direct bilirubin (DB), γ-GT or matrix metalloproteinase-7 (MMP-7) levels. These findings will promote early diagnosis for BA and hence improve the survival.

Conditions

  • Hepatobiliary Disease
  • Biliary Atresia
  • Neonatal Cholestasis

Interventions

DIAGNOSTIC_TEST

Dry blood spot screening

Dry blood spot measurement of biomarker for screening biliary atresia

Sponsors & Collaborators

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Wei Cai, Pro · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-03-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03898765 on ClinicalTrials.gov